ArticleCureus2025
Oxymetazoline and Blepharoptosis: A Case Series and Proposed Treatment Algorithm.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blepharoptosis, characterized by drooping upper eyelids, affects vision and daily life. Traditional management includes observation, pharmacological treatments, and surgery, though not all cases necessitate surgical intervention. Pharmacologic treatments such as apraclonidine and phenylephrine eyedrops have been used but are limited by significant adverse effects, including pupil dilation and ocular/systemic side effects. Recently, oxymetazoline ophthalmic solution, approved by the FDA in 2020, has emerged as a promising alternative, showing improvement in visual field and eyelid elevation with minimal adverse effects. This study aims to elucidate the utilization of oxymetazoline in patients with blepharoptosis by the senior author and to propose a treatment algorithm tailored for these patients. Oxymetazoline was administered to five patients with blepharoptosis in the absence of contraindications. Response to the medication was assessed clinically, and a treatment algorithm was devised. Following the oxymetazoline test, the subsequent course of action was determined as follows: a favorable response in the oxymetazoline test indicated a benefit from an internal ptosis repair with or without a blepharoplasty. A minimal or less than optimal response after the test suggested the necessity for external ptosis repair, possibly accompanied by blepharoplasty. Furthermore, in cases of asymmetric ptosis or unilateral ptosis, the test was employed on the affected or more ptotic eye initially to serve as an interdependence test. This also allowed the surgeon to determine if a unilateral or bilateral repair was necessary. Oxymetazoline offers a valuable therapeutic option for blepharoptosis, serving as both a diagnostic tool and a bridging therapy before surgery. Its extended duration of effectiveness and favorable safety profile make it an attractive choice for patients. The proposed treatment algorithm simplifies decision-making for clinicians and enhances patient satisfaction and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.